SavedAdd your journal

Journals / Eskişehir Teknik Üniversitesi Bilim ve Teknoloji Dergisi - C Yaşam Bilimleri Ve Biyoteknoloji / 2018 / Cilt: 7 Sayı: 1

ATTRACTIVE APPROACHES in DRUG DELIVERY: BIO-BASED CARRIERS for siRNA TARGETING

Zülal Yalınca
Şükrü Tüzmen
Pages
74–89
Publication Date
2018-02-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Additionally, cancer genetics and metabolic disorders including obesity and diabetes pertaining to the progress in clinical applications have been highlighted.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Functional characterization of genes can be determined by disruption of gene expression.
📊
Key Findings & Data:This provides powerful approach in designing novel treatment strategies.
💡
Conclusion & Impact:Additionally, cancer genetics and metabolic disorders including obesity and diabetes pertaining to the progress in clinical applications have been highlighted.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:siRNA · bio-therapeutics · post-transcriptional regulation

Abstract

Functional characterization of genes can be determined by disruption of gene expression. This provides powerful approach in designing novel treatment strategies. RNA interference (RNAi) is a natural phenomenon that can aid in the study of post-transcriptional regulation of genes. This mechanism can be stimulated via introduction of double stranded RNA (dsRNA) in a cell. Synthetic short/small interfering RNAs (siRNA) can be utilized to trigger down-regulation of desired genes via transfecting into mammalian cells. Recently, utilization of bio-based polymers has been an attractive approach in drug delivery for medical applications. This review article describes the advantages of exploiting bio-based polymeric carriers for siRNA targeting, as bio-therapeutics. Here, we report the current developments, safety and delivery of bio-based siRNAs via polymeric carriers. Additionally, cancer genetics and metabolic disorders including obesity and diabetes pertaining to the progress in clinical applications have been highlighted.

🔖

Cite This Article

Yalınca, Z., Tüzmen, Ş. (2018). ATTRACTIVE APPROACHES in DRUG DELIVERY: BIO-BASED CARRIERS for siRNA TARGETING. Eskişehir Teknik Üniversitesi Bilim ve Teknoloji Dergisi - C Yaşam Bilimleri Ve Biyoteknoloji, Cilt: 7 Sayı: 1, 74–89. https://ajindex.com/articles/755389

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. . Wang X, Wang YQ, Chen Z, Shin DM: Advances of Cancer Therapy by Nanotechnology. Cancer Research and Treatment
  2. 2009, 41:1-11. [2]. Chapman EJ, Carrington JC: Specialization and evolution of endogenous small RNA pathways. Nature Reviews Genetics
  3. 2007, 8:884-896. [3]. Lee SJ, Son S, Yhee JY, Choi K, Kwon IC, Kim SH, Kim K: Structural modification of siRNA for efficient gene silencing. Biotechnol Adv.: 2013, 31:491-503. [4]. Lee SJ, Kim MJ, Kwon IC, Roberts TM: Delivery strategies and potential targets for siRNA in major cancer types. Adv. Drug Deliver. Rev.
  4. 2016, 104:2-15. [5]. Tuzmen S, Tuzmen P, Arora S, Mousses S, Azorsa D: RNAi-based functional pharmacogenomics. Methods Mol. Biol.
  5. 2011, 700:271-290. [6]. Kang S, Hong YS: RNA interference in infectious tropical diseases. Korean Journal of Parasitology
  6. 2008, 46:1-15. [7]. Ding SW, Voinnet O: Antiviral immunity directed by small RNAs. Cell
  7. 2007, 130:413-426. [8]. Obbard DJ, Gordon KHJ, Buck AH, Jiggins FM: The evolution of RNAi as a defence against viruses and transposable elements. Philosophical Transactions of the Royal Society B-Biological Sciences 2009, 364:99-115. [9]. Saurabh S, Vidyarthi AS, Prasad D: RNA interference: concept to reality in crop improvement. Planta
  8. 2014, 239:543-564. [10]. Tijsterman M, Plasterk RHA: Dicers at RISC: The mechanism of RNAi. Cell
  9. 2004, 117:1-3. [11]. Elbashir SM, Lendeckel W, Tuschl T: RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes & Development
  10. 2001, 15:188-200. [12]. Xu CF, Wang J: Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences
  11. 2015, 10:1-12. [13]. Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S: Functional evidence implicating S100P in prostate cancer progression. Int. J. Cancer
  12. 2008, 123:330-339. [14]. Savas S, Azorsa DO, Jarjanazi H, Ibrahim-Zada I, Gonzales IM, Arora S, Henderson MC, Choi YH, Briollais L, Ozcelik H, Tuzmen S: NCI60 Cancer Cell Line Panel Data and RNAi Analysis Help Identify EAF2 as a Modulator of Simvastatin and Lovastatin Response in HCT-116 Cells. Plos One
  13. 2011, 6. [15]. Sarett SM, Nelson CE, Duvall CL: Technologies for controlled, local delivery of siRNA. J. Control Release
  14. 2015, 218:94-113. [16]. Conde J, Ambrosone A, Hernandez Y, Tian FR, McCully M, Berry CC, Baptista PV, Tortiglione C, de la Fuente JM: 15 years on siRNA delivery: Beyond the State-of-the-Art on inorganic nanoparticles for RNAi therapeut